Is Green Tea Extract Cardiometabolic Meta-Analysis safe?

Updated October 2026

Quick Answer

Green Tea Extract Cardiometabolic Meta-Analysis has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: 1 Metabolic syndrome (MetS) is a multifactorial disorder characterized by a cluster of metabolic and cardiovascular abnormalities, including central obesity, dyslipidemia, insulin resistance, and hypertension, which collectively increase the risk of suffering from metabolic diseases such as type 2 diabetes and cardiovascular diseases in the long term [].

Key Takeaways

  • 011 Metabolic syndrome (MetS) is a multifactorial disorder characterized by a cluster of metabolic and cardiovascular abnormalities, including central obesity, dyslipidemia, insulin resistance, and hypertension, which collectively increase the risk of suffering from metabolic diseases such as type 2 diabetes and cardiovascular diseases in the long term []. [de la Fuente-Muñoz Mario (2026)]
  • 02Impairment at any step, such as decreased IRS phosphorylation or PI3K/Akt activity, leads to defective glucose transport, reduced glycogen synthesis, increased lipolysis, and the development of insulin resistance []. [de la Fuente-Muñoz Mario (2026)]
  • 036 7 8 9 10 11 One of the most important factors contributing to the development of insulin resistance is increased adiposity, and particularly visceral adiposity [], a condition that is present in most patients with MetS []. [de la Fuente-Muñoz Mario (2026)]
  • 042 3 4 5 Central to the pathogenesis of MetS is insulin resistance, a condition characterized by the disruption of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway, a critical mediator of insulin’s metabolic actions in key metabolic tissues such as liver, muscle, and adipose tissue [,]. [de la Fuente-Muñoz Mario (2026)]
The current Migaku evidence database contains 2 reusable source documents for Green Tea Extract Cardiometabolic Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts. - 1 Metabolic syndrome (MetS) is a multifactorial disorder characterized by a cluster of metabolic and cardiovascular abnormalities, including central obesity, dyslipidemia, insulin resistance, and hypertension, which collectively increase the risk of suffering from metabolic diseases such as type 2 diabetes and cardiovascular diseases in the long term []. [de la Fuente-Muñoz Mario (2026); evidence level 4] - Impairment at any step, such as decreased IRS phosphorylation or PI3K/Akt activity, leads to defective glucose transport, reduced glycogen synthesis, increased lipolysis, and the development of insulin resistance []. [de la Fuente-Muñoz Mario (2026); evidence level 4] - 6 7 8 9 10 11 One of the most important factors contributing to the development of insulin resistance is increased adiposity, and particularly visceral adiposity [], a condition that is present in most patients with MetS []. [de la Fuente-Muñoz Mario (2026); evidence level 4] - 2 3 4 5 Central to the pathogenesis of MetS is insulin resistance, a condition characterized by the disruption of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway, a critical mediator of insulin’s metabolic actions in key metabolic tissues such as liver, muscle, and adipose tissue [,]. [de la Fuente-Muñoz Mario (2026); evidence level 4] - Low-grade chronic inflammation and oxidative stress accompany obesity [,] and are at least partly attributed to gut barrier dysfunction that promotes endotoxemia-associated inflammation []. [Sasaki Geoffrey Y. (2022); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Enhanced Effects of Complex Tea Extract and the Postbiotic BPL1 ® HT on Ameliorating the Cardiometabolic Alterations Associated with Metabolic Syndrome in Mice
  2. Catechin Bioavailability Following Consumption of a Green Tea Extract Confection Is Reduced in Obese Persons without Affecting Gut Microbial-Derived Valerolactones